Celgene’s Pomalidomide Helps in Myeloma After Others Fail

Celgene Corp., the world’s fourth-largest biotechnology company, said its experimental medicine for multiple myeloma helped fight the cancer after other therapies failed.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.